PREVALENCE AND PATTERN OF DYSLIPIDAEMIA AND ASSOCIATED FACTORS IN NAÏVE TYPE 2 DIABETES MELLITUS PATIENTS: A CROSS-SECTIONAL STUDY FROM WESTERN UTTAR PRADESH

MUKESH DUBE; SUNDAR PAL SINGH; NEERAJ KHARE

doi:10.22159/ajpcr.2022.v15i8.45438

Authors

MUKESH DUBE Department of General Medicine, Rajshree Medical College and Research Institute, Bareilly, Uttar Pradesh, India.
SUNDAR PAL SINGH Department of Obstetrics and Gynaecology, SHKM Government Medical College, Nuh, Haryana, India. https://orcid.org/0000-0002-8310-5996
NEERAJ KHARE Department of Community Medicine, Atal Bihari Vajpayee Government Medical College, Vidisha, Madhya Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i8.45438

Keywords:

Diabetes mellitus, Dyslipidemia, Insulin resistance, Cardiovascular, Atherogenic

Abstract

Objective: The present study was conducted with an objective to study prevalence and pattern of dyslipidemia in newly diagnosed type 2 diabetes mellitus patients.

Methods: From August 2021 to March 2022, 161 participants participated in the trial. After a night of fasting, skilled medical laboratory technicians drew 5 ml of blood from each study subject and performed anthropometric measurements on them.

Results: 110 patients, or 68.9% of the entire group, had dyslipidemia. About 3.7% (n=6) of the individuals had atherogenic dyslipidemia. Among 2.5% and 23.6% of the participants, high TC (total cholesterol) and low HDL (high-density lipoprotein), respectively, were found to be isolated dyslipidemias. Significantly more hypertensives (77.9%), people with abnormal fasting glucose levels (80.2%), those with elevated postprandial glucose levels (78.8%), and people with larger waist circumference had dyslipidemia (76.0%).

Conclusion: Our study showed that diabetic patients have a significant prevalence of dyslipidemia. The main public health issue in underdeveloped nations is dyslipidemia, which also serves as a standalone risk factor for developing cardiovascular disease (CVD). In addition, it complicates the progression of CVD in diabetic individuals and raises mortality when combined with other risk factors like high blood pressure.

Downloads

Download data is not yet available.

Author Biographies

MUKESH DUBE, Department of General Medicine, Rajshree Medical College and Research Institute, Bareilly, Uttar Pradesh, India.

Assistant Professor, Department of Medicine, Rajshree Medical College and Research Center, Bareilly, Uttar Pradesh

NEERAJ KHARE, Department of Community Medicine, Atal Bihari Vajpayee Government Medical College, Vidisha, Madhya Pradesh, India.

Associate Professor, Department of General Medicine, SHKM Government Medical College, Nuh

References

American Diabetes Association. 9. Cardiovascular disease and risk management: Standards of medical care in diabetes-2018. Diabetes Care 2018;41:S86-104.

Catapano AL, Reiner Ž, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Atherosclerosis 2011;217:1-44.

Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo- Fernandez R, et al. European cardiovascular disease statistics. Eur Heart Netw 2008;3:11-35.

Federation ID. IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017. p. 905-11.

Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017;70:1-25.

Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, et al. World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. Lancet Glob Health 2019;7:e1332-45.

Mendis S. The contribution of the Framingham heart study to the prevention of cardiovascular disease: A global perspective. Prog Cardiovasc Dis 2010;53:10-4.

Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease. Circ Cardiovasc Qual Outcomes 2019;12:e005375.

Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA 2001;286:1468-74.

Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: A reappraisal. J Clin Endocrinol Metabol 2003;88:4525-32.

Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, Walldius G. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am J Cardiol 2006;97:943-6.

Mohan V, Venkatraman JV, Pradeepa R. Epidemiology of cardiovascular disease in Type 2 diabetes: The Indian scenario. J Diabetes Sci Technol 2010;4:158-70.

Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian council of medical research-India diabetes (ICMR-INDIAB) study. Diabetologia 2011;54:3022-7.

Iyengar SS, Puri R, Narasingan SN. Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2016: Part 1-executive summary. J Clin Prev Cardiol 2016;5:51-61.

Dixit AK, Dey R, Suresh A, Chaudhuri S, Panda AK, Mitra A, et al. The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda hospital. J Diabetes Metab Disord 2014;13:58.

Abbate SL, Brunzell JD. Pathophysiology of hyperlipidemia in diabetes mellitus. J Cardiovas pharmacol 1990;16:S1-7.

UK prospective diabetes study group. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997;20:1683-7.

Pandya H, Lakhani JD, Dadhania J, Trivedi A. The prevalence and pattern of dyslipidemia among Type 2 diabetic rural based hospital in Gujarat, India. Ind J Clin Prac 2012;22:36-44.